Keyword: Bayer

Because about 30% of payment will come in the form of Elanco stock, Bayer won't entirely rid itself of animal health just yet.

Roche’s targeted cancer drug Rozlytrek is officially cleared for a U.S. launch—and in not one, but two indications.

Eli Lilly spinoff Elanco emerged atop the list of interested buyers of Bayer's animal health unit. A deal could be wrapped up soon.

Analysts figure the Bayer drug's better safety profile could help it carve out market share against Pfizer and Astellas’ Xtandi and J&J’s Erleada.

At its July meeting, experts with the European Medicines Agency's CHMP recommended approvals for four novel drugs, a Mylan generic and more.

It turns out that Bayer was not the only pharma company targeted by the Winnti cyberattack. Roche also was a victim. 

Bayer is recalling two lots of its top-selling drugs after a labeling mishap led to them being filled with the wrong hemophilia medicines. 

Bayer's revamp just took another big step forward. After selling off Coppertone, the company agreed to hive off Dr. Scholl’s for $585 million.

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

Bayer’s for-sale animal health unit has been stirring up interest among private equity players—but the company may have another buyer in mind.